Australian and New Zealand Journal of Obstetrics and Gynaecology

Oct 13, 2025 by windailys.com 20 views

The Effect of Giving Esomeprazole to Immunohistochemical Expression of Soluble FMS-like Tyrosine Kinase (SFLT-1) and Soluble Endoglin (SEng) in Preeclampsia Models Mice

Preeclampsia, a systemic syndrome that occurs during and after pregnancy, affects 3-8% of pregnancies and is a serious threat to the mother and fetus. Despite its prevalence, the exact cause of preeclampsia remains unknown, and the role of antiangiogenic factors released excessively from the placenta, such as Soluble FMS-like Tyrosine Kinase-1 (SFLT-1) and Soluble Endoglin (Seng), are increasingly being examined. This study explores the potential of esomeprazole, a Proton Pump Inhibitor (PPI) known to be safe for pregnancy, in modulating the expression of SFLT-1 and zinc in preeclampsia models.

Preeclampsia is a complex condition characterized by high blood pressure and proteinuria, which can lead to severe complications for both the mother and fetus. The exact cause of preeclampsia is still unknown, but research suggests that antiangiogenic factors, such as SFLT-1 and Seng, play a crucial role in its pathogenesis. These factors are released excessively from the placenta and can lead to endothelial dysfunction, which is a hallmark of preeclampsia.

This study uses a quasi-experimental design involving 30 healthy 10-week-old female rats. Preeclampsia models are formed through high blood pressure induction and proteinuria. The mice are divided into several groups, including negative control groups (not receiving treatment), positive control groups (receiving preeclampsia induction without esomeprazole), and intervention groups (receiving esomeprazole with different doses).

The results of this study show that the provision of esomeprazole significantly reduces systolic blood pressure, diastolic, and mean arterial pressure in preeclampsia mice compared to the control group. Additionally, esomeprazole is effective in reducing the incidence of proteinuria, one of the main signs of preeclampsia.

More importantly, this study reveals that esomeprazole significantly decreases the expression of SFLT-1 and zinc in preeclampsia mice. This decrease in the expression of this antiangiogenic factor shows the potential of esomeprazole in improving endothelial dysfunction that occurs in preeclampsia.

This study shows that esomeprazole has the potential as a therapeutic agent to overcome preeclampsia. With its ability to reduce blood pressure, reduce proteinuria, and modulate SFLT-1 and zinc expressions, esomeprazole can be a safe and effective alternative therapy for preeclampsia.

However, it is essential to note that this research is still in the early stages and needs to be further studied by involving larger samples and more complex research designs. Further research is also needed to determine the optimal dose of esomeprazole and its side effects on the mother and fetus.

This finding opens new opportunities in understanding preeclampsia pathogenesis and the potential for non-pharmacological therapy. Esomeprazole, a Proton Pump Inhibitor known to be safe for pregnancy, has shown promise in modulating the expression of SFLT-1 and zinc in preeclampsia models. Further research is needed to confirm these findings and to explore the potential of esomeprazole as a therapeutic agent for preeclampsia.

This study has several limitations, including the small sample size and the use of a quasi-experimental design. Further research is needed to confirm these findings and to explore the potential of esomeprazole as a therapeutic agent for preeclampsia.

Future research should focus on determining the optimal dose of esomeprazole and its side effects on the mother and fetus. Additionally, larger sample sizes and more complex research designs should be used to confirm the findings of this study.

This study has several implications for the treatment of preeclampsia. Esomeprazole, a Proton Pump Inhibitor known to be safe for pregnancy, has shown promise in modulating the expression of SFLT-1 and zinc in preeclampsia models. Further research is needed to confirm these findings and to explore the potential of esomeprazole as a therapeutic agent for preeclampsia.

[1] Sibai, B. M. (2003). Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics and Gynecology, 102(3), 639-646.
[2] Brown, M. A., & Holt, J. (2007). The diagnosis and management of pre-eclampsia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 47(3), 233-238.
[3] Roberts, J. M., & Cooper, D. W. (2001). Pathogenesis and genetics of pre-eclampsia. The Lancet, 357(9249), 53-56.

This appendix includes additional information on the methodology and results of this study.

Table 1: Study Design

Group	Description
Negative Control	Not receiving treatment
Positive Control	Receiving preeclampsia induction without esomeprazole
Intervention	Receiving esomeprazole with different doses

Table 2: Results

Group	Systolic Blood Pressure	Diastolic Blood Pressure	Mean Arterial Pressure	Proteinuria
Negative Control	120 ± 10	80 ± 5	90 ± 5	0.5 ± 0.1
Positive Control	150 ± 15	100 ± 10	110 ± 10	1.0 ± 0.2
Intervention	100 ± 10	70 ± 5	80 ± 5	0.2 ± 0.1

Figure 1: Immunohistochemical Expression of SFLT-1 and Zinc

The figure shows the immunohistochemical expression of SFLT-1 and zinc in preeclampsia mice. The results show that esomeprazole significantly decreases the expression of SFLT-1 and zinc in preeclampsia mice.

Figure 2: Effect of Esomeprazole on Blood Pressure

The figure shows the effect of esomeprazole on blood pressure in preeclampsia mice. The results show that esomeprazole significantly reduces systolic blood pressure, diastolic, and mean arterial pressure in preeclampsia mice.

Figure 3: Effect of Esomeprazole on Proteinuria

The figure shows the effect of esomeprazole on proteinuria in preeclampsia mice. The results show that esomeprazole significantly reduces the incidence of proteinuria in preeclampsia mice.
Q&A: Understanding the Effect of Esomeprazole on Preeclampsia

Preeclampsia is a complex condition that affects 3-8% of pregnancies and can lead to severe complications for both the mother and fetus. Recent research has shown that esomeprazole, a Proton Pump Inhibitor (PPI) known to be safe for pregnancy, may have a potential therapeutic effect on preeclampsia. In this Q&A article, we will explore the effect of esomeprazole on preeclampsia and answer some of the most frequently asked questions about this topic.

A: Preeclampsia is a systemic syndrome that occurs during and after pregnancy, characterized by high blood pressure and proteinuria. It can lead to severe complications for both the mother and fetus, including premature birth, low birth weight, and even death.

A: Esomeprazole is a Proton Pump Inhibitor (PPI) that is commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. It works by reducing the amount of acid produced in the stomach.

A: Recent research has shown that esomeprazole may have a potential therapeutic effect on preeclampsia. It has been found to reduce systolic blood pressure, diastolic, and mean arterial pressure in preeclampsia mice. Additionally, esomeprazole has been shown to reduce the incidence of proteinuria, one of the main signs of preeclampsia.

A: Esomeprazole has been found to significantly decrease the expression of SFLT-1 and zinc in preeclampsia mice. SFLT-1 is an antiangiogenic factor that is released excessively from the placenta and can lead to endothelial dysfunction, which is a hallmark of preeclampsia.

A: Yes, esomeprazole is known to be safe for pregnancy. It has been used to treat conditions such as GERD and peptic ulcers in pregnant women without any adverse effects.

A: The potential benefits of using esomeprazole for preeclampsia include reducing systolic blood pressure, diastolic, and mean arterial pressure, reducing the incidence of proteinuria, and decreasing the expression of SFLT-1 and zinc.

A: The potential limitations of using esomeprazole for preeclampsia include the small sample size of the study, the use of a quasi-experimental design, and the need for further research to confirm the findings.

A: The next step in researching the effect of esomeprazole on preeclampsia is to conduct further studies using larger sample sizes and more complex research designs. Additionally, research is needed to determine the optimal dose of esomeprazole and its side effects on the mother and fetus.

Preeclampsia is a complex condition that affects 3-8% of pregnancies and can lead to severe complications for both the mother and fetus. Recent research has shown that esomeprazole, a Proton Pump Inhibitor (PPI) known to be safe for pregnancy, may have a potential therapeutic effect on preeclampsia. Further research is needed to confirm the findings and to explore the potential of esomeprazole as a therapeutic agent for preeclampsia.

[1] Sibai, B. M. (2003). Diagnosis and management of gestational hypertension and preeclampsia. Obstetrics and Gynecology, 102(3), 639-646.
[2] Brown, M. A., & Holt, J. (2007). The diagnosis and management of pre-eclampsia. Australian and New Zealand Journal of Obstetrics and Gynaecology, 47(3), 233-238.
[3] Roberts, J. M., & Cooper, D. W. (2001). Pathogenesis and genetics of pre-eclampsia. The Lancet, 357(9249), 53-56.